This review of the evidence was funded by AHRQ for the USPSTF. The investigators acknowledge the contributions of Kim Villemyer for her help in preparing the full evidence report and the manuscript; Christina Bougatsos for her help in preparing the manuscript; and Andrew Hamilton, M.L.S., M.S., for conducting the literature searches. They also thank Mark Helfand, M.D., M.P.H.; Heidi D. Nelson, M.D., M.P.H.; David Lanier, M.D.; members of the U.S. Preventive Services Task Force; and reviewers for their contributions to this project.
This study was conducted by the Oregon Evidence-based Practice Center, Portland, OR, under contract to AHRQ. Contract No. 290-02-0024, Rockville, MD.
1. Wortley PM, Fleming PL. AIDS in women in the United States. Recent trends. JAMA 1997;278:911-6.
2. Lee LM, Fleming PL. Trends in human immunodeficiency virus diagnoses among women in the United States, 1994-1998. J Am Med Womens Assoc 2001;56:94-9.
3. Lindegren ML, Byers RH Jr, Thomas P, Davis SF, Caldwell B, Rogers M, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 1999;282:531-8.
4. Bulterys M, Nolan ML, Jamieson DJ, Dominguez K, Fowler MG. Advances in the prevention of mother-to-child HIV-1 transmission: current issues, future challenges. AIDScience 2002. Accessed at www.aidscience.org/Articles/aidscience017.asp on 22 March 2005.
5. U.S. Department of Health and Human Services. Reducing obstetrician barriers to offering HIV testing. 2002. Accessed at www.cdc.gov/hiv/projects/perinatal/materials/ps_oig.pdf on 22 March 2005.
6. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2003 (Volume 15). Accessed at www.cdc.gov/hiv/stats/2003SurveillanceReport.pdf on 22 March 2005.
7. Revised recommendations for HIV screening of pregnant women. MMWR Recomm Rep 2001;50:63-85; quiz CE1-19a2-CE6-19a2.
8. Mandelbrot L, Mayaux MJ, Bongain A, Berrebi A, Moudoub-Jeanpetit Y, Benifla JL, et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group. Am J Obstet Gynecol 1996;175:661-7.
9. Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992;340:585-8.
10. Nduati R. Breastfeeding and HIV-1 infection. A review of current literature. Adv Exp Med Biol 2000;478:201-10.
11. Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999;341:385-93.
12. Shapiro DE, Sperling RS, Mandelbrot L, Britto P, Cunningham BE. Risk factors for perinatal human immunodeficiency virus transmission in patients receiving zidovudine prophylaxis. Pediatric AIDS Clinical Trials Group protocol 076 Study Group. Obstet Gynecol 1999;94:897-908.
13. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk for perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999;341:394-402.
14. Mother-to-child transmission of human immunodeficiency virus in Italy: temporal trends and determinants of infection. The Italian Collaborative Study on HIV infection in pregnancy. Hum Reprod 1999;14:242-6.
15. HIV-infected pregnant women and vertical transmission in Europe since 1986. European collaborative study. AIDS 2001;15:761-70.
16. Mofenson LM. Advances in the prevention of vertical transmission of human immunodeficiency virus. Semin Pediatr Infect Dis. 2003;14:295-308.
17. U.S. Department of Health and Human Services. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. 2005. Accessed at http://aidsinfo.nih.gov/guidelines/perinatal/PER_022405.pdf on 22 March 2005.
18. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed. Alexandria, VA: International Medical Publishing; 1996.
19. ACOG committee opinion. Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. Number 219, August 1999. Committee on Obstetric Practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1999;66:305-6.
20. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002;51:1-52.
21. Centers for Disease Control and Prevention. Recommended adult immunization schedule by age group and medical conditions United States, 2003-2004. 2003. Accessed at www.cdc.gov/nip/recs/adult-schedule.pdf on 28 June 2004.
22. Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm Rep 2001;50:1-57; quiz CE1-19a1-CE6-19a1.
23. Chou R, Smits AK, Huffman LH, Fu R, Korthuis PT. Screening for human immunodeficiency virus in pregnant women: systematic evidence synthesis. Available at www.ahrq.gov/clinic/serfiles.htm
24. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001;20:21-35.
25. U.S. Preventive Services Task Force. Screening for human immunodeficiency virus infection. In: Guide to Clinical Preventive Services. Accessed at www.ahrq.gov/clinic/2ndcps/hiv.pdf on 11 March 2005.
26. Centers for Disease Control and Prevention. AIDS cases, deaths, and persons living with AIDS by year, 1985-2002—United States. HIV/AIDS Surveillance Report 2002 (Volume 14). Accessed at www.cdc.gov/hiv/stats/hasr1402.htm on 2 December 2004.
27. Peterman TA, Todd KA, Mupanduki I. Opportunities for targeting publicly funded human immunodeficiency virus counseling and testing. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:69-74.
28. Fehrs LJ, Fleming D, Foster LR, McAlister RO, Fox V, Modesitt S, et al. Trial of anonymous versus confidential human immunodeficiency virus testing. Lancet 1988;2:379-82.
29. Barbacci MB, Dalabetta GA, Repke JT, Talbot BL, Charache P, Polk BF, et al. Human immunodeficiency virus infection in women attending an inner-city prenatal clinic: ineffectiveness of targeted screening. Sex Transm Dis 1990;17:122-6.
30. Pulver WP, Glebatis D, Wade N, Birkhead GS, Smith P. Trends from an HIV seroprevalence study among childbearing women in New York State from 1988 through 2000: a valuable epidemiologic tool. Arch Pediatr Adolesc Med 2004;158:443-8.
31. Hawken J, Chard T, Jeffries DJ, Costeloe K, Grant K, Ward F, et al. Evaluation of an antenatal HIV testing programme in an inner London health district. Br J Obstet Gynaecol 1994;101:960-4.
32. Ellerbrock TV, Lieb S, Harrington PE, Bush TJ, Schoenfisch SA, Oxtoby MJ, et al. Heterosexually transmitted human immunodeficiency virus infection among pregnant women in a rural Florida community. N Engl J Med 1992;327:1704-9.
33. Lindsay MK, Peterson HB, Feng TI, Slade BA, Willis S, Klein L. Routine antepartum human immunodeficiency virus infection screening in an inner-city population. Obstet Gynecol 1989;74:289-94.
34. Fehrs LJ, Hill D, Kerndt PR, Rose TP, Henneman C. Targeted HIV screening at a Los Angeles prenatal/family planning health center. Am J Public Health 1991;81:619-22.
35. Landesman S, Minkoff H, Holman S, McCalla S, Sijin O. Serosurvey of human immunodeficiency virus infection in parturients. Implications for human immunodeficiency virus testing programs of pregnant women. JAMA 1987;258:2701-3.
36. U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR Recomm Rep 1995;44:1-15.
37. Perinatal human immunodeficiency virus testing. Provisional Committee on Pediatric AIDS, American Academy of Pediatrics. Pediatrics 1995;95:303-7.
38. Wortley PM, Lindegren ML, Fleming PL. Successful implementation of perinatal HIV prevention guidelines: a multistate surveillance evaluation. MMWR Recomm Rep 2001;50(RR-6):17-28.
39. Lewis R, O'Brien JM, Ray DT, Sibai BM. The impact of initiating a human immunodeficiency virus screening program in an urban obstetric population. Am J Obstet Gynecol 1995;173:1329-33.
40. Mercey D, Helps BA, Copas A, Petruckevitch A, Johnson AM, Spencer J. Voluntary universal antenatal HIV testing. Br J Obstet Gynaecol 1996;103:1129-33.
41. From the Centers for Disease Control and Prevention. Interpretation and use of the western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. JAMA 1989;262:3395-7.
42. Update: serologic testing for HIV-1 antibody—United States, 1988 and 1989. MMWR Morb Mortal Wkly Rep 1990;39:380-3.
43. Kleinman S, Busch MP, Hall L, Thomson R, Glynn S, Gallahan D, et al. False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation. Retrovirus Epidemiology Donor Study. JAMA 1998;280:1080-5.
44. Celum CL, Coombs RW, Jones M, Murphy V, Fisher L, Grant C, et al. Risk factors for repeatedly reactive HIV-1 EIA and indeterminate western blots. A population-based case—control study. Arch Intern Med 1994;154:1129-37.
45. Centers for Disease Control and Prevention. Rapid HIV antibody testing during labor and delivery for women of unknown HIV status. 2004. Accessed at www.cdc.gov/hiv/rapid_testing/materials/Labor&DeliveryRapidTesting.pdf on 20 July 2004.
46. Update: HIV counseling and testing using rapid tests—United States, 1995. MMWR Morb Mortal Wkly Rep 1998;47:211-5.
47. Bulterys M, Jamieson DJ, O'Sullivan MJ, Cohen MH, Maupin R, Nesheim S, et al. Rapid HIV-1 testing during labor: a multicenter study. JAMA 2004;292:219-23.
48. Webber MP, Demas P, Enriquez E, Shanker R, Oleszko W, Beatrice ST, et al. Pilot study of expedited HIV-1 testing of women in labor at an inner-city hospital in New York City. Am J Perinatol 2001;18:49-57.
49. Ramalingam S, Kannangai R, Raj A A, Jesudason MV, Sridharan G. Rapid particle agglutination test for human immunodeficiency virus: hospital-based evaluation. J Clin Microbiol 2002;40:1553-4.
50. Chalermchockcharoenkit A, Louisirirotchnakul S, Roongpisuthipong A, Sirimai K, Sutchritpongsa P, Wasi C. Rapid human immunodeficiency virus diagnostic test during the intrapartum period in pregnant women who did not receive antenatal care. J Med Assoc Thai 2002;85:703-8.
51. Lien TX, Tien NT, Chanpong GF, Cuc CT, Yen VT, Soderquist R, et al. Evaluation of rapid diagnostic tests for the detection of human immunodeficiency virus types 1 and 2, hepatitis B surface antigen, and syphilis in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg 2000;62:301-9.
52. Mashu A, Mbizvo MT, Makura E, Bopoto R, Madzime S, Chipato T, et al. Evaluation of rapid on-site clinic HIV test, combined with counseling [Letter]. AIDS 1997;11:932-3.
53. Koblavi-Dème S, Maurice C, Yavo D, Sibailly TS, N'guessan K, Kamelan-Tano Y, et al. Sensitivity and specificity of human immunodeficiency virus rapid serologic assays and testing algorithms in an antenatal clinic in Abidjan, Ivory Coast. J Clin Microbiol 2001;39:1808-12.
54. O'Connell RJ, Merritt TM, Malia JA, VanCott TC, Dolan MJ, Zahwa H, et al. Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol 2003;41:2153-5.
55. Uni-Gold Recombigen HIV. [Package insert, #045-138]. Bray, Ireland: Trinity Biotech. Revised March 2004.
56. Reveal Rapid HIV-1 Antibody Test. [Package insert, #FDAINS0065]. Halifax, Nova Scotia, Canada: MedMira Laboratories; rev. 0/1.
57. Reynolds SJ, Ndongala LM, Luo CC, Mwandagalirwa K, Losoma AJ, Mwamba KJ, et al. Evaluation of a rapid test for the detection of antibodies to human immunodeficiency virus type 1 and 2 in the setting of multiple transmitted viral subtypes. Int J STD AIDS 2002;13:171-3.
58. OraQuick Rapid HIV-1 Antibody Test [Package insert, #3001-0951]. Bethlehem, PA: OraSure Technologies; revised October 2003.
59. Bhore AV, Sastry J, Patke D, Gupte N, Bulakh PM, Lele S, et al. Sensitivity and specificity of rapid HIV testing of pregnant women in India. Int J STD AIDS 2003;14:37-41.
60. Sansom SL, Jamieson DJ, Farnham PG, Bulterys M, Fowler MG. Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission. Obstet Gynecol 2003;102:782-90.
61. Sheon AR, Fox HE, Alexander G, Buck A, Higgins A, McDermott SM, et al. Misdiagnosed HIV infection in pregnant women: implications for clinical care. Public Health Rep 1994;109:694-9.
62. Doran TI, Parra E. False-positive and indeterminate human immunodeficiency virus test results in pregnant women. Arch Fam Med 2000;9:924-9.
63. Samson L, King S. Evidence-based guidelines for universal counseling and offering of HIV testing in pregnancy in Canada. CMAJ 1998;158:1449-57.
64. Lester P, Partridge JC, Chesney MA, Cooke M. The consequences of a positive prenatal HIV antibody test for women. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:341-9.
65. Koenig LJ, Whitaker DJ, Royce RA, Wilson TE, Callahan MR, Fernandez MI, et al. Violence during pregnancy among women with or at risk for HIV infection. Am J Public Health 2002;92:367-70.
66. Green L, Ardron C, Catalan J. HIV, childbirth and suicidal behaviour: a review. Hosp Med 2000;61:311-4.
67. Nakchbandi IA, Longenecker JC, Ricksecker MA, Latta RA, Healton C, Smith DG. A decision analysis of mandatory compared with voluntary HIV testing in pregnant women. Ann Intern Med 1998;128:760-7.
68. Irwin KL, Valdiserri RO, Holmberg SD. The acceptability of voluntary HIV antibody testing in the United States: a decade of lessons learned. AIDS 1996;10:1707-17.
69. HIV testing among pregnant women—United States and Canada, 1998-2001. MMWR Morb Mortal Wkly Rep 2002;51:1013-6.
70. Lansky A, Jones JL, Frey RL, Lindegren ML. Trends in HIV testing among pregnant women: United States, 1994-1999. Am J Public Health 2001;91:1291-3.
71. Simpson WM, Johnstone FD, Boyd FM, Goldberg DJ, Hart GJ, Gormley SM, et al. A randomised controlled trial of different approaches to universal antenatal HIV testing: uptake and acceptability and Annex: Antenatal HIV testing—assessment of a routine voluntary approach. Health Technol Assess 1999;3:1-112.
72. Lindsay MK, Adefris W, Peterson HB, Williams H, Johnson J, Klein L. Determinants of acceptance of routine voluntary human immunodeficiency virus testing in an inner-city prenatal population. Obstet Gynecol 1991;78:678-80.
73. Royce RA, Walter EB, Fernandez MI, Wilson TE, Ickovics JR, Simonds RJ, et al. Barriers to universal prenatal HIV testing in 4 US locations in 1997. Am J Public Health 2001;91:727-33.
74. Stringer EM, Stringer JS, Cliver SP, Goldenberg RL, Goepfert AR. Evaluation of a new testing policy for human immunodeficiency virus to improve screening rates. Obstet Gynecol 2001;98:1104-8.
75. Jayaraman GC, Preiksaitis JK, Larke B. Mandatory reporting of HIV infection and opt-out prenatal screening for HIV infection: effect on testing rates. CMAJ 2003;168:679-82.
76. Joo E, Carmack A, Garcia-Buñuel E, Kelly CJ. Implementation of guidelines for HIV counseling and voluntary HIV testing of pregnant women. Am J Public Health 2000;90:273-6.
77. Malonza IM, Richardson BA, Kreiss JK, Bwayo JJ, Stewart GC. The effect of rapid HIV-1 testing on uptake of perinatal HIV-1 interventions: a randomized clinical trial. AIDS 2003;17:113-8.
78. Prenatal HIV testing and antiretroviral prophylaxis at an urban hospital—Atlanta, Georgia, 1997-2000. MMWR Morb Mortal Wkly Rep 2004;52:1245-8.
79. From the Centers for Disease Control and Prevention. Progress toward elimination of perinatal HIV infection—Michigan, 1993-2000. MMWR Morb Mortal Wkly Rep 2002;51:93-7.
80. Wade NA, Zielinski MA, Butsashvili M, McNutt LA, Warren BL, Glaros R, et al. Decline in Perinatal HIV Transmission in New York State (1997-2000). J Acquir Immune Defic Syndr 2004;36:1075-82.
81. Fiscus SA, Adimora AA, Funk ML, Schoenbach VJ, Tristram D, Lim W, et al. Trends in interventions to reduce perinatal human immunodeficiency virus type 1 transmission in North Carolina. Pediatr Infect Dis J 2002;21:664-8.
82. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484-94.
83. Dominguez KL, Lindegren ML, D'Almada PJ, Peters VB, Frederick T, Rakusan TA, et al. Increasing trend of Cesarean deliveries in HIV-infected women in the United States from 1994 to 2000. J Acquir Immune Defic Syndr 2003;33:232-8.
84. Working Group on Mother-to-Child Transmission of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:506-10.
85. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80.
86. Brocklehurst P. Interventions for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2002;(1):CD000102.
87. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 2004;36:772-6.
88. Determinants of mother-to-infant human immunodeficiency virus 1 transmission before and after the introduction of zidovudine prophylaxis. Arch Pediatr Adolesc Med 2002;156:915-21.
89. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40:458-65.
90. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla JL, Burgard M, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001;285:2083-93.
91. Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002;288:189-98.
92. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004;351:217-28.
93. Lallemant M, Jourdain G, Le Coeur S, Kim S, Koetsawang S, Comeau AM, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med 2000;343:982-91.
94. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999;353:773-80.
95. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002;359:1178-86.
96. Wiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin ST, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999;353:781-5.
97. Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. Diminution de la Transmission Mere-Enfant. Lancet 1999;353:786-92.
98. Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, et al. A multicenter randomized, controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003;187:725-35.
99. Taha TE, Kumwenda NI, Gibbons A, Broadhead RL, Fiscus S, Lema V, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 2003;362:1171-7.
100. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003;362:859-68.
101. Taha TE, Kumwenda NI, Hoover DR, Fiscus SA, Kafulafula G, Nkhoma C, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized, controlled trial. JAMA 2004;292:202-9.
102. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802.
103. John GC, Richardson BA, Nduati RW, Mbori-Ngacha D, Kreiss JK. Timing of breast milk HIV-1 transmission: a meta-analysis. East Afr Med J 2001;78:75-9.
104. Coutsoudis A, Dabis F, Fawzi W, Gaillard P, Haverkamp G, Harris DR, et al. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004;189:2154-66.
105. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000;283:1167-74.
106. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. The European Mode of Delivery Collaboration. Lancet 1999;353:1035-9.
107. The mode of delivery and the risk for vertical transmission of human immunodeficiency virus type 1—a meta-analysis of 15 prospective cohort studies. The International Perinatal HIV Group. N Engl J Med 1999;340:977-87.
108. Ioannidis JP, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads < 1000 copies/mL. J Infect Dis 2001;183:539-45.
109. Massad LS, Springer G, Jacobson L, Watts H, Anastos K, Korn A, et al. Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS 2004;18:281-6.
110. Lindsay MK, Grant J, Peterson HB, Willis S, Nelson P, Klein L. The impact of knowledge of human immunodeficiency virus serostatus on contraceptive choice and repeat pregnancy. Obstet Gynecol 1995;85:675-9.
111. Blair JM, Hanson DL, Jones JL, Dworkin MS. Trends in pregnancy rates among women with human immunodeficiency virus. Obstet Gynecol 2004;103:663-8.
112. Bedimo AL, Bessinger R, Kissinger P. Reproductive choices among HIV-positive women. Soc Sci Med 1998;46:171-9.
113. Temmerman M, Moses S, Kiragu D, Fusallah S, Wamola IA, Piot P. Impact of single session postpartum counseling of HIV infected women on their subsequent reproductive behaviour. AIDS Care 1990;2:247-52.
114. Selwyn PA, Carter RJ, Schoenbaum EE, Robertson VJ, Klein RS, Rogers MF. Knowledge of HIV antibody status and decisions to continue or terminate pregnancy among intravenous drug users. JAMA 1989;261:3567-71.
115. U.S. Department of Health and Human Services. Safety and toxicity of individual antiretroviral agents in pregnancy. 2005. Accessed at http://aidsinfo.nih.gov/guidelines/perinatal/ST_022405.pdf on 9 March 2005.
116. Watts DH, Balasubramanian R, Maupin RT Jr, Delke I, Dorenbaum A, Fiore S, et al. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 2004;190:506-16.
117. Morris AB, Cu-Uvin S, Harwell JI, Garb J, Zorrilla C, Vajaranant M, et al. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr 2000;25:306-11.
118. Edwards SG, Larbalestier N, Hay P, de Ruiter A, Welch J, Taylor GP, et al. Experience of nevirapine use in a London cohort of HIV-infected pregnant women. HIV Med 2001;2:89-91.
119. Lyons F, Hopkins S, McGeary A, Sheehan G, Bergin C, Mulcahy F. Nevirapine tolerability in HIV infected women in pregnancy—a word of caution [Abstract]. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, 13—17 July 2003. Accessed at www.iasociety.org/abstract/show.asp?abstract_id=11081 on 3 May 2005.
120. Eastman PS, Shapiro DE, Coombs RW, Frenkel LM, McSherry GD, Britto P, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998;177:557-64.
121. Minkoff H, Hershow R, Watts DH, Frederick M, Cheng I, Tuomala R, et al. The relationship of pregnancy to human immunodeficiency virus disease progression. Am J Obstet Gynecol 2003;189:552-9.
122. Bardeguez AD, Shapiro DE, Mofenson LM, Coombs R, Frenkel LM, Fowler MG, et al. Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J Acquir Immune Defic Syndr 2003;32:170-81.
123. Sperling RS, Shapiro DE, McSherry GD, Britto P, Cunningham BE, Culnane M, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS 1998;12:1805-13.
124. Watts DH, Lambert J, Stiehm ER, Harris DR, Bethel J, Mofenson L, et al. Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr 2003;33:585-93.
125. Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002;186:181-8.
126. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-7.
127. Morris L, Pillay C, Chezzi C, Lupondwana P, Ntsala M, Levin L, et al. Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine [Letter]. AIDS 2003;17:1698-700.
128. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004;351:229-40.
129. Marcollet A, Goffinet F, Firtion G, Pannier E, Le Bret T, Brival ML, et al. Differences in postpartum morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery. Am J Obstet Gynecol 2002;186:784-9.
130. Rodriguez EJ, Spann C, Jamieson D, Lindsay M. Postoperative morbidity associated with cesarean delivery among human immunodeficiency virus-seropositive women. Am J Obstet Gynecol 2001;184:1108-11.
131. Semprini AE, Castagna C, Ravizza M, Fiore S, Savasi V, Muggiasca ML, et al. The incidence of complications after caesarean section in 156 HIV-positive women. AIDS 1995;9:913-7.
132. Read JS, Tuomala R, Kpamegan E, Zorrilla C, Landesman S, Brown G, et al. Mode of delivery and postpartum morbidity among HIV-infected women: the women and infants transmission study. J Acquir Immune Defic Syndr 2001;26:236-45.
133. Watts DH, Lambert JS, Stiehm ER, Bethel J, Whitehouse J, Fowler MG, et al. Complications according to mode of delivery among human immunodeficiency virus-infected women with CD4 lymphocyte counts of < or = 500/microL. Am J Obstet Gynecol 2000;183:100-7.
134. Taylor GP, Low-Beer N. Antiretroviral therapy in pregnancy: a focus on safety. Drug Saf 2001;24:683-702.
135. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and the risk for an adverse outcome. N Engl J Med 2002;346:1863-70.
136. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003;32:380-7.
137. Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003;22:782-9.
138. Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003;33:175-83.
139. Divi RL, Walker VE, Wade NA, Nagashima K, Seilkop SK, Adams ME, et al. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. AIDS 2004;18:1013-21.
140. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-9.
141. Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, Desguerre I, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003;17:1769-85.
142. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 2000;25:261-8.
143. Lindegren ML, Rhodes P, Gordon L, Fleming P. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann NY Acad Sci 2000;918:222-35.
144. Bulterys M, Nesheim S, Abrams EJ, Palumbo P, Farley J, Lampe M, et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann NY Acad Sci 2000;918:212-21.
145. Dominguez K, Bertolli J, Fowler M, Peters V, Ortiz I, Melville S, et al. Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children < or = 5 years of age, Pediatric Spectrum of HIV Disease project (PSD), USA. Ann NY Acad Sci 2000;918:236-46.
146. Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell K, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 1999;281:151-7.
147. Hanson IC, Antonelli TA, Sperling RS, Oleske JM, Cooper E, Culnane M, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:463-7.
148. Human immunodeficiency virus screening. Joint statement of the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists. Pediatrics 1999;104(1 Pt 1):128.
149. Stoto MA, Almario DA, McCormick MC, eds. Reducing the Odds: Preventing Perinatal Transmission of HIV in the United States. Washington, DC: National Academy Pr; 1999.
150. Analysis of HIV-1 clinical trials: statistical magic? The AVANTI Steering Committee. Lancet 1999;353:2061-4.
151. Fowler MG, Mofenson L, McConnell M. The interface of perinatal HIV prevention, antiretroviral drug resistance, and antiretroviral treatment: what do we really know? [Editorial]. J Acquir Immune Defic Syndr 2003;34:308-11.
152. Nolan M, Fowler MG, Mofenson LM. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J Acquir Immune Defic Syndr 2002;30:216-29.
153. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47:1-30.
154. Ihaka R, Gentleman R. R: A language for data analysis and graphics. J Comput Graph Stat 1996;5:299-314.
This document is in the public domain within the United States. For information on reprinting, contact Randie Siegel, Director, Division of Printing and Electronic Publishing, Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850.
Requests for linking or to incorporate content in electronic resources should be sent to: info@ahrq.gov.
This article and the corresponding recommendation statement are available from the AHRQ Web site (http://www.preventiveservices.ahrq.gov). The recommendation is also available on the Web site of the National Guideline Clearinghouse™ (http://www.guideline.gov).
The authors of this article are responsible for its contents, including any clinical or treatment recommendations. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Source: U.S. Preventive Services Task Force. Ann Intern Med 2005:143:38-54.
AHRQ Publication No. 05-0579-B
Current as of May 2005
Internet Citation:
Prenatal Screening for HIV: Review of the Evidence for the U.S. Preventive Services Task Force. AHRQ Publication No. 05-0579-B, May 2005. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/uspstf05/hiv/hivprenat.htm
USPSTF Topic Index
USPSTF Clinical Categories
U.S. Preventive Services Task Force
Clinical Information
AHRQ Home Page